New Insights Into Cancer Drug Resistance

Epigenetic Mechanisms of Tumor Initiation and Evolution
Bradley E. Bernstein, MD, PhD

Developing Therapies for Transcriptionally Addicted Tumors
Nathanael Gray, PhD

Targets That Defy Effective Therapy

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers
Ryan B. Corcoran, MD, PhD

Hematologic Malignancies

FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia
Richard M. Stone, MD

Dihydroorotate Dehydrogenase: An Unexpected Metabolic Vulnerability in Acute Myeloid Leukemia
David B. Sykes, MD, PhD

Fellows Forum

Genomics of a Mitochondria-Rich Tumor
Raj Gopal, MD, PhD

Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering
Zuzana Tothova, MD, PhD

Neo-antigens and the Immune Response

T-Cell Therapy: Current Applications and Future Directions
Marcela V. Maus, MD, PhD

Addressing Cancer Clonal Heterogeneity: Developing Personalized Neoantigen-Based Cancer Vaccines
Catherine J. Wu, MD

Molecular Tumor Board

Moderator: Aditya Bardia, MD, MPH
Panelists: Darrell Borger, PhD; Leif W. Ellisen, MD, PhD; Justin F. Gainor, MD